reviewed april 2026|next review october 2026|88 physicians psi has verified|189879 published studies
Alpha-1 Antitrypsin Peptide (VIRIP)
VIRIP (Virus Inhibitory Peptide) is a 20-amino acid peptide fragment of alpha-1 antitrypsin (AAT) that potently inhibits HIV-1 entry by binding the gp41 fusion peptide, representing a novel discovery of antiviral activity from a naturally occurring serine protease inhibitor whose parent protein is FDA-approved for augmentation therapy.
Evidence landscape: 189879 published studies
VIRIP-specific research is a small subset of the alpha-1 antitrypsin literature. The parent protein has extensive clinical data.
- 20 Human
- 147 Animal
- 33 Reviews
- 189679 Other research
VIRIP was identified as a naturally occurring peptide fragment of alpha-1 antitrypsin with potent anti-HIV activity. It blocks HIV entry by a mechanism distinct from existing antiretroviral drugs.
Binds the gp41 fusion peptide of HIV-1, physically preventing the conformational changes needed for viral membrane fusion with host cells.
Early research stage (animal studies and cell-based assays). Optimized analogs have been designed with enhanced potency, but no clinical trials have been conducted for the peptide itself. The parent protein (AAT) is FDA-approved for a different indication.
PSI Assessment
Alpha-1 antitrypsin is best known as the protein that protects lungs from enzyme damage, with FDA-approved augmentation therapy for people who lack it. But a fragment of this protein, VIRIP, was discovered to have a completely unexpected function: it blocks HIV from entering human cells. VIRIP binds to a critical part of the virus (the gp41 fusion peptide) and physically prevents it from fusing with host cell membranes. Optimized versions show enhanced antiviral potency. The gap between this laboratory discovery and clinical application is significant, but the finding that the body produces its own anti-HIV peptide is scientifically notable.
A naturally occurring anti-HIV peptide hidden within alpha-1 antitrypsin. Blocks viral entry through gp41 fusion peptide binding. Early research stage (cell-based assays) only.
VIRIP binds to the hydrophobic N-terminal region of the gp41 fusion peptide of HIV-1. This interaction physically blocks the conformational changes that gp41 must undergo to fuse the viral envelope with the host cell membrane. The mechanism is distinct from all FDA-approved antiretroviral drugs, representing a potential new class of HIV entry inhibitors. Optimized analogs have been developed through rational design with enhanced antiviral potency. The parent protein (AAT) also has anti-inflammatory properties through serine protease inhibition and NF-kB modulation, which are being studied for Type 1 diabetes islet protection and COPD (chronic obstructive pulmonary disease) management.
What the evidence supports
VIRIP (Virus Inhibitory Peptide), a 20-amino acid fragment of alpha-1 antitrypsin, blocks HIV-1 entry by binding the gp41 fusion peptide in cell-based assays. Optimized analogs show enhanced antiviral potency. The parent protein alpha-1 antitrypsin is FDA-approved for augmentation therapy in AAT deficiency. The discovery that an endogenous protein fragment has antiviral activity is well-documented.
What is not yet established
Clinical efficacy of VIRIP or its analogs as HIV therapeutics. Whether in vitro antiviral activity translates to in vivo viral suppression. Pharmacokinetics and delivery approaches for therapeutic use. How VIRIP-based approaches would compare to existing HIV entry inhibitors.
Research Evidence
The findings below cover the VIRIP antiviral mechanism, the parent protein's FDA-approved applications, and the expanded research directions.
Evidence by condition
Evidence dimensions for the alpha-1 antitrypsin peptide. Parent protein applications have clinical data. VIRIP antiviral applications are at the laboratory stage.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| HIV Entry Inhibition | ||||
| AAT Deficiency (Parent Protein) | ||||
| Type 1 Diabetes (Parent Protein) |
VIRIP blocks HIV-1 entry by binding the gp41 fusion peptide in cell-based assays. The interaction is structurally characterized and distinct from the mechanism of any approved antiretroviral drug.
A novel mechanism of HIV entry inhibition discovered in a naturally occurring protein fragment. The structural characterization supports rational analog design.
Optimized VIRIP analogs designed through rational modification show significantly enhanced antiviral potency compared to the native peptide sequence.
Analog optimization demonstrates that the antiviral activity can be improved pharmacologically. However, no analog has progressed beyond laboratory testing.
The parent protein alpha-1 antitrypsin is FDA-approved for augmentation therapy in AAT deficiency. It is also being studied in Phase II trials for Type 1 diabetes islet protection and for COPD management in AAT-deficient patients.
The parent protein has an established clinical safety profile. The expanded indications research is based on AAT's anti-inflammatory properties beyond protease inhibition.
20 Human|147 Animal|33 Reviews
View all 189879 indexed studiesHow Alpha-1 Antitrypsin Peptide (VIRIP) Works
VIRIP is a 20-amino acid peptide fragment of alpha-1 antitrypsin that inhibits HIV-1 entry by binding the gp41 fusion peptide, preventing viral membrane fusion with host cells.
Acts as a shield protecting tissues from damage by immune enzymes.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
VIRIP interacts with the hydrophobic N-terminal region of the gp41 fusion peptide of HIV-1. This binding physically prevents the conformational transition of gp41 from the pre-hairpin intermediate to the six-helix bundle structure required for membrane fusion. The parent protein, alpha-1 antitrypsin (SERPINA1), is a serine protease inhibitor that primarily inhibits neutrophil elastase. It also modulates NF-kB signaling, dendritic cell function, and macrophage activation. FDA-approved augmentation therapy provides exogenous AAT to patients with genetic deficiency.
What is Alpha-1 Antitrypsin Peptide (VIRIP) being studied for?
Researchers are studying Alpha-1 Antitrypsin Peptide (VIRIP) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Alpha-1 Antitrypsin Peptide (VIRIP) overall. This means a compound can have human studies for one condition but only animal data for another.
HIV Entry Inhibition
·Animal StudiesVIRIP blocks HIV-1 entry through gp41 fusion peptide binding in cell-based assays. Optimized analogs show enhanced antiviral potency. Represents a novel mechanism distinct from existing antiretroviral drugs.
Limitations: All data is from cell-based assays (laboratory studies only). No animal or human studies for the peptide itself. The gap between in vitro viral inhibition and clinical antiviral therapy is substantial.
AAT Deficiency (Parent Protein)
·FDA ApprovedAlpha-1 antitrypsin augmentation therapy is FDA-approved for patients with genetic AAT deficiency, providing exogenous protease inhibitor to protect lungs from neutrophil elastase damage.
Limitations: This refers to the parent protein, not the VIRIP peptide fragment. The indications are different.
Type 1 Diabetes (Parent Protein)
·Animal StudiesPhase II trials are studying AAT for islet cell protection in Type 1 diabetes, based on the protein's anti-inflammatory properties.
Limitations: Early clinical data from small trials. Whether AAT provides meaningful islet protection requires larger studies.
Safety and Regulatory Status
FDA Status: The parent protein (AAT) is FDA-approved for augmentation therapy. The VIRIP peptide fragment is not FDA-approved or in clinical development.
Availability: VIRIP is a research compound only. AAT augmentation therapy is available by prescription for diagnosed AAT deficiency.
Class context: Derived from a naturally occurring protein with decades of clinical safety data. The VIRIP peptide fragment itself has no human safety data.
The parent protein has decades of clinical safety data through FDA-approved augmentation therapy. The VIRIP peptide fragment has no human safety data. It is a research compound.
Questions and Comparisons
Questions the evidence raises for a Alpha-1 Antitrypsin Peptide (VIRIP) discussion.
Comparison and Related Research
VIRIP is most often compared with other antiviral peptides and HIV entry inhibitors.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Identified VIRIP (Virus Inhibitory Peptide) as a 20-amino acid fragment of alpha-1 antitrypsin that potently blocks HIV-1 entry by binding to the gp41 fusion peptide, representing a novel endogenous antiviral defense mechanism.Munch J et al., 2007 in Cell. View on PubMed
- 2.First-in-human clinical evaluation of an optimized VIRIP analog in HIV-infected patients, demonstrating antiviral activity and establishing proof-of-concept for the endogenous peptide-derived entry inhibitor approach.Forssmann WG et al., 2010 in J Med Chem. View on PubMed
- 3.Reviewed the biology of alpha-1 antitrypsin as a serine protease inhibitor, including the FDA-approved augmentation therapy for AAT deficiency and the broader anti-inflammatory properties of the protein and its fragments.Janciauskiene S et al., 2011 in J Biol Chem. View on PubMed
- 4.Earlier characterization of alpha-1 antitrypsin-derived anti-HIV activity, providing the foundation for the later discovery of VIRIP as the specific fragment responsible for blocking viral entry.Shapiro L et al., 2003 in Proc Natl Acad Sci USA. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.